Evaxion A/S (NASDAQ:EVAX) Raised to Buy at Wall Street Zen

Evaxion A/S (NASDAQ:EVAX) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Several other equities research analysts have also recently issued reports on the stock. Lake Street Capital lowered their target price on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. JonesTrading started coverage on shares of Evaxion A/S in a research note on Tuesday, March 10th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Maxim Group began coverage on shares of Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Evaxion A/S Stock Performance

NASDAQ EVAX opened at $4.26 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. The stock’s 50 day simple moving average is $3.81 and its 200-day simple moving average is $4.65. The company has a market cap of $35.53 million, a PE ratio of -3.23 and a beta of 0.28. Evaxion A/S has a 1-year low of $1.20 and a 1-year high of $12.15.

Evaxion A/S (NASDAQ:EVAX) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.30 EPS for the quarter. As a group, equities research analysts anticipate that Evaxion A/S will post -0.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Evaxion A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVAX. Wesbanco Bank Inc. acquired a new position in shares of Evaxion A/S in the 4th quarter valued at $48,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Evaxion A/S during the 4th quarter worth about $38,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of Evaxion A/S during the 4th quarter worth about $72,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.